Market Overview

According to fortune business insights, the global drug discovery services market size was valued at USD 19.76 billion in 2025. The market is projected to grow from USD 21.11 billion in 2026 to USD 36.22 billion by 2034, exhibiting a CAGR of 7.0% during the forecast period. North America dominated the drug discovery services market with a market share of 39.62% in 2025.

The analysis shows that the market is being driven by the increasing prevalence of chronic conditions, rising outsourcing by pharmaceutical and biotechnology companies, and the expansion of biotechnology pipelines. For instance, according to 2024 statistics from the World Health Organization (WHO), around 50 million people have epilepsy globally. This trend indicates a strong demand for innovative drugs and effective therapies worldwide.

Major Players Profiled in the Market Report:• Charles River Laboratories (U.S.)• WuXi AppTec (China)• Labcorp (U.S.)• Evotec (Germany)• Eurofins Scientific (Luxembourg)• Sygnature (U.K.)• Pharmaron (China)• Aragen Life Sciences Ltd. (India)• Sai Life Sciences Limited (India)• Crown Bioscience (U.S.)

SegmentsIncreasing Delivery of Compounds to Propel Chemistry Services Segment GrowthBased on service type, the market is classified into chemistry services and biology services. The chemistry services segment holds the largest market share and dominates the market owing to its increasing use across almost every stage of small-molecule drug discovery, driving rising demand among pharmaceutical and biotechnology companies.

Increasing Approval of Novel Drugs to Drive Lead Optimization Segment ExpansionBy discovery phase, the market is categorized into target identification & validation, hit identification, hit-to-lead, lead optimization, and others. The lead optimization segment is leading the market (26.8% share in 2025) as outsourcing these services helps meet the need for integrated chemistry and biology capabilities, resulting in increased approval of novel drugs.

Growing Approval of Small Molecules to Dominate Small Molecules SegmentBased on drug type, the market is segmented into small molecules and biologics. The small molecules segment holds the largest market share owing to the rising prevalence of chronic diseases and the advantages of small molecules, leading to increased approval of these therapies.

Increasing Prevalence of Cancer to Dominate the Market Due to its High Preference among ConsumersBased on therapeutic area, the market is segmented into oncology, neurological diseases, infectious diseases, cardiovascular diseases, and others. The oncology segment holds the largest market share owing to the increasing prevalence of cancer and the growing adoption of outsourcing drug discovery services.

Pharmaceutical & Biotechnological Companies’ Leading Growth Owed to Increasing Demand for Innovative DrugsBased on end user, the market is split into pharmaceutical & biotechnological companies, academic & research institutes, and others. The pharmaceutical & biotechnological companies segment leads market growth (77.0% share in 2026) owing to the increasing demand for innovative drugs and the growing number of companies in this space.Geographically, the market is studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

For detailed market insights: https://www.fortunebusinessinsights.com/drug-discovery-services-market-117651

Report CoverageThe report offers:• Major growth drivers, restraining factors, opportunities, and potential challenges for the market.• Comprehensive insights into regional developments.• List of major industry players.• Key strategies adopted by the market players.• The latest industry developments include product launches, partnerships, mergers, and acquisitions.

Drivers & RestraintsIncreasing Prevalence of Chronic Disorders to Propel Market GrowthThe rapid growth in chronic conditions, including cardiovascular disorders and cancer, has raised the demand for innovative drugs and effective therapies. This has led to increased outsourcing of discovery services such as assay development, lead optimization, and ADME/Tox studies, boosting the drug discovery services market growth.However, the high cost associated with advanced drug discovery technologies may hamper market growth. Sophisticated platforms require significant upfront capital investment, trained professionals, and maintenance contracts, which increases the overall cost and makes adoption challenging for smaller companies.

Regional InsightsRising Outsourcing and Digital Tool Adoption Propel Market Growth in North AmericaNorth America holds the dominant drug discovery services market share and is projected to experience growth during the forecast period. The region’s growth is attributed to the growing prevalence of chronic diseases, rising adoption of outsourcing services, and the increasing use of digital tools and automation in the drug discovery process.Asia Pacific is one of the fastest-growing regions in the market. The growth is attributed to the expansion of drug discovery outsourcing networks and rising R&D infrastructure development in developing nations, including China and India.

Drug Discovery Services Market Future GrowthThe drug discovery services market is experiencing robust growth, fueled by the increasing adoption of digital tools, artificial intelligence, and automation to shorten discovery timelines and improve R&D productivity. Pharmaceutical and biotech companies are increasingly using AI/ML platforms for target identification, lead optimization, and virtual screening. Additionally, there is a major opportunity in the expansion of outsourcing networks across emerging countries like China and India, driven by developing R&D infrastructure, rising healthcare expenditure, and government initiatives supporting biotechnology innovation.

Competitive LandscapeGrowing Adoption of Acquisitions and Partnerships to Propel Market GrowthThe market features prominent players like Wuxi AppTec and Charles River Laboratories. These leading companies are accelerating growth through strategic initiatives such as acquisitions, partnerships, and expanding their service portfolios to strengthen their global presence. Their proactive approach to adapting and evolving with industry demands continues to fuel the market’s momentum.

Key Industry Development• May 2026: Concept Life Sciences partnered with OpenBench to accelerate hit identification for biotech companies through a fee-for-success model.